国际生殖健康/计划生育杂志 ›› 2024, Vol. 43 ›› Issue (5): 353-360.doi: 10.12280/gjszjk.20240349
• 论著 • 下一篇
肖楠, 李永程, 姚义鸣, 孙红文, 姚汝强, 陈泳君, 殷宇辰, 罗海宁()
收稿日期:
2024-07-22
出版日期:
2024-09-15
发布日期:
2024-09-19
通讯作者:
罗海宁
E-mail:luohn163@163.com
基金资助:
XIAO Nan, LI Yong-cheng, YAO Yi-ming, SUN Hong-wen, YAO Ru-qiang, CHEN Yong-jun, YIN Yu-chen, LUO Hai-ning()
Received:
2024-07-22
Published:
2024-09-15
Online:
2024-09-19
Contact:
LUO Hai-ning
E-mail:luohn163@163.com
摘要:
目的: 评估卵巢微环境内邻苯二甲酸酯(phthalates,PAEs)暴露与炎性因子水平的关系。方法: 纳入2020年4—12月接受体外受精/卵胞质内单精子注射-胚胎移植治疗的64例患者,测定其卵泡液内10种邻苯二甲酸酯代谢物(phthalate metabolites,mPAEs)及2种炎性因子的水平。通过多元线性回归模型评估卵巢微环境内mPAEs暴露与炎性因子水平的关系,并进一步按年龄分层分析。结果: 卵泡液中邻苯二甲酸单丁酯(MBP)水平与肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)水平(β=0.446,P=0.003)及白细胞介素-6(interleukin-6,IL-6)水平(β=0.425,P=0.003)均呈正相关,邻苯二甲酸(2-乙基-5-氧己基)单酯(MEOHP)水平与TNF-α水平呈正相关(β=0.411,P=0.019)。在分层分析中,年龄≥30岁组卵泡液中MBP水平与TNF-α水平(β=0.667,P=0.000)及IL-6水平(β=0.407,P=0.028)均呈正相关,在年龄<30岁组内未观察到mPAEs与炎症因子之间存在关联。结论: PAEs暴露可影响卵泡液中炎性因子水平,提示PAEs暴露可能带来卵巢微环境炎症负荷的改变。
肖楠, 李永程, 姚义鸣, 孙红文, 姚汝强, 陈泳君, 殷宇辰, 罗海宁. 卵巢微环境内邻苯二甲酸酯暴露与炎性因子水平的关系[J]. 国际生殖健康/计划生育杂志, 2024, 43(5): 353-360.
XIAO Nan, LI Yong-cheng, YAO Yi-ming, SUN Hong-wen, YAO Ru-qiang, CHEN Yong-jun, YIN Yu-chen, LUO Hai-ning. Associations between Phthalates Exposure and Inflammatory Cytokines in Ovarian Microenvironment[J]. Journal of International Reproductive Health/Family Planning, 2024, 43(5): 353-360.
特征 | n | TNF-α(pg/mL) | IL-6(pg/mL) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
检测值 | Z或H | P | 检测值 | Z或H | P | |||||||
年龄(岁) | -0.997 | 0.319 | -0.418 | 0.676 | ||||||||
<35 | 53 | 22.57(19.97,28.03) | 15.06(12.26,19.24) | |||||||||
≥35 | 11 | 21.37(18.97,24.99) | 12.96(12.26,19.94) | |||||||||
BMI(kg/m2) | -0.626 | 0.531 | -0.875 | 0.382 | ||||||||
BMI≤23.9 | 30 | 22.07(19.57,25.75) | 14.36(12.03,17.79) | |||||||||
BMI>23.9 | 34 | 22.57(19.97,28.64) | 14.82(12.26,22.27) | |||||||||
居住地 | -0.009 | 0.993 | -2.368 | 0.018 | ||||||||
城镇 | 53 | 22.57(19.47,28.03) | 15.52(12.50,20.17) | |||||||||
农村 | 11 | 21.57(20.37,25.19) | 12.26(10.87,14.13) | |||||||||
受教育水平 | 0.762 | 0.683 | 0.700 | 0.705 | ||||||||
初中及以下 | 16 | 21.17(19.37,25.16) | 13.78(11.74,17.62) | |||||||||
高中、中专及技校 | 10 | 21.97(20.77,25.44) | 14.82(12.56,15.75) | |||||||||
本科及以上 | 38 | 22.67(19.37,29.90) | 15.41(12.26,20.52) | |||||||||
家庭月收入(元) | 0.030 | 0.985 | 3.650 | 0.161 | ||||||||
<3 000 | 6 | 22.17(20.77,24.13) | 14.01(11.92,17.21) | |||||||||
3 000~6 000 | 20 | 22.07(19.67,27.01) | 13.20(11.63,15.41) | |||||||||
>6 000 | 38 | 22.37(19.32,29.45) | 16.34(12.85,20.52) | |||||||||
吸烟 | -0.238 | 0.812 | -1.377 | 0.169 | ||||||||
从不吸烟 | 59 | 22.17(19.97,27.42) | 14.82(12.26,19.48) | |||||||||
曾经吸烟现已戒烟 | 5 | 25.19(18.77,55.63) | 11.80(10.63,28.67) | |||||||||
饮酒情况 | -0.490 | 0.624 | -0.786 | 0.432 | ||||||||
否或戒酒 | 54 | 22.27(19.87,27.82) | 14.48(12.26,18.31) | |||||||||
偶尔饮酒 | 10 | 21.97(19.12,26.00) | 17.15(11.92,33.55) | |||||||||
不孕类型 | -0.020 | 0.984 | -0.047 | 0.962 | ||||||||
原发不孕 | 31 | 22.17(20.37,25.19) | 14.59(12.26,19.01) | |||||||||
继发不孕 | 33 | 22.37(19.27,28.84) | 15.06(11.80,19.71) | |||||||||
不孕年限(年) | -0.463 | 0.643 | -0.221 | 0.825 | ||||||||
<3 | 19 | 23.58(19.57,28.43) | 15.06(11.10,22.97) | |||||||||
≥3 | 45 | 21.77(19.77,27.21) | 14.59(12.38,18.90) | |||||||||
不孕原因 | 4.621 | 0.202 | 2.785 | 0.426 | ||||||||
女方因素 | 41 | 21.77(19.27,27.52) | 14.36(12.15,17.62) | |||||||||
男方因素 | 7 | 22.17(20.97,77.19) | 12.26(11.10,20.41) | |||||||||
双方因素 | 10 | 24.99(22.42,33.90) | 16.34(12.79,25.53) | |||||||||
不明原因 | 6 | 21.07(19.52,22.62) | 17.73(13.66,33.73) | |||||||||
D3 FSH(U/L) | 0.001 | 0.999 | -1.221 | 0.222 | ||||||||
<10 | 60 | 22.27(19.97,27.27) | 14.48(12.26,18.31) | |||||||||
≥10 | 4 | 26.56(17.83,63.49) | 26.46(12.50,57.86) | |||||||||
D3 AFC(个) | 0.969 | 0.616 | 1.830 | 0.400 | ||||||||
<7 | 17 | 21.77(19.27,26.96) | 15.87(12.21,21.22) | |||||||||
7~12 | 30 | 21.37(19.27,31.08) | 13.43(12.38,26.46) | |||||||||
>12 | 17 | 22.77(20.27,25.09) | 13.66(11.92,15.99) | |||||||||
COS方案 | -0.101 | 0.920 | -0.666 | 0.505 | ||||||||
长方案 | 34 | 21.97(20.87,25.75) | 14.24(12.21,19.59) | |||||||||
拮抗剂方案 | 30 | 22.87(19.17,30.57) | 14.94(12.50,19.83) | |||||||||
Gn剂量(IU) | -1.054 | 0.292 | -0.900 | 0.368 | ||||||||
<2 512 | 32 | 22.77(20.22,28.43) | 14.36(12.09,18.14) | |||||||||
≥2 512 | 32 | 21.37(19.42,26.40) | 14.82(12.44,21.92) | |||||||||
Gn天数(d) | -1.138 | 0.255 | -0.838 | 0.402 | ||||||||
<12 | 59 | 21.77(19.57,27.62) | 14.59(12.26,19.01) | |||||||||
≥12 | 5 | 24.99(22.76,27.92) | 15.52(12.96,28.78) |
表1 不同特征人群FF中炎症因子水平比较 [M(P25,P75)]
特征 | n | TNF-α(pg/mL) | IL-6(pg/mL) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
检测值 | Z或H | P | 检测值 | Z或H | P | |||||||
年龄(岁) | -0.997 | 0.319 | -0.418 | 0.676 | ||||||||
<35 | 53 | 22.57(19.97,28.03) | 15.06(12.26,19.24) | |||||||||
≥35 | 11 | 21.37(18.97,24.99) | 12.96(12.26,19.94) | |||||||||
BMI(kg/m2) | -0.626 | 0.531 | -0.875 | 0.382 | ||||||||
BMI≤23.9 | 30 | 22.07(19.57,25.75) | 14.36(12.03,17.79) | |||||||||
BMI>23.9 | 34 | 22.57(19.97,28.64) | 14.82(12.26,22.27) | |||||||||
居住地 | -0.009 | 0.993 | -2.368 | 0.018 | ||||||||
城镇 | 53 | 22.57(19.47,28.03) | 15.52(12.50,20.17) | |||||||||
农村 | 11 | 21.57(20.37,25.19) | 12.26(10.87,14.13) | |||||||||
受教育水平 | 0.762 | 0.683 | 0.700 | 0.705 | ||||||||
初中及以下 | 16 | 21.17(19.37,25.16) | 13.78(11.74,17.62) | |||||||||
高中、中专及技校 | 10 | 21.97(20.77,25.44) | 14.82(12.56,15.75) | |||||||||
本科及以上 | 38 | 22.67(19.37,29.90) | 15.41(12.26,20.52) | |||||||||
家庭月收入(元) | 0.030 | 0.985 | 3.650 | 0.161 | ||||||||
<3 000 | 6 | 22.17(20.77,24.13) | 14.01(11.92,17.21) | |||||||||
3 000~6 000 | 20 | 22.07(19.67,27.01) | 13.20(11.63,15.41) | |||||||||
>6 000 | 38 | 22.37(19.32,29.45) | 16.34(12.85,20.52) | |||||||||
吸烟 | -0.238 | 0.812 | -1.377 | 0.169 | ||||||||
从不吸烟 | 59 | 22.17(19.97,27.42) | 14.82(12.26,19.48) | |||||||||
曾经吸烟现已戒烟 | 5 | 25.19(18.77,55.63) | 11.80(10.63,28.67) | |||||||||
饮酒情况 | -0.490 | 0.624 | -0.786 | 0.432 | ||||||||
否或戒酒 | 54 | 22.27(19.87,27.82) | 14.48(12.26,18.31) | |||||||||
偶尔饮酒 | 10 | 21.97(19.12,26.00) | 17.15(11.92,33.55) | |||||||||
不孕类型 | -0.020 | 0.984 | -0.047 | 0.962 | ||||||||
原发不孕 | 31 | 22.17(20.37,25.19) | 14.59(12.26,19.01) | |||||||||
继发不孕 | 33 | 22.37(19.27,28.84) | 15.06(11.80,19.71) | |||||||||
不孕年限(年) | -0.463 | 0.643 | -0.221 | 0.825 | ||||||||
<3 | 19 | 23.58(19.57,28.43) | 15.06(11.10,22.97) | |||||||||
≥3 | 45 | 21.77(19.77,27.21) | 14.59(12.38,18.90) | |||||||||
不孕原因 | 4.621 | 0.202 | 2.785 | 0.426 | ||||||||
女方因素 | 41 | 21.77(19.27,27.52) | 14.36(12.15,17.62) | |||||||||
男方因素 | 7 | 22.17(20.97,77.19) | 12.26(11.10,20.41) | |||||||||
双方因素 | 10 | 24.99(22.42,33.90) | 16.34(12.79,25.53) | |||||||||
不明原因 | 6 | 21.07(19.52,22.62) | 17.73(13.66,33.73) | |||||||||
D3 FSH(U/L) | 0.001 | 0.999 | -1.221 | 0.222 | ||||||||
<10 | 60 | 22.27(19.97,27.27) | 14.48(12.26,18.31) | |||||||||
≥10 | 4 | 26.56(17.83,63.49) | 26.46(12.50,57.86) | |||||||||
D3 AFC(个) | 0.969 | 0.616 | 1.830 | 0.400 | ||||||||
<7 | 17 | 21.77(19.27,26.96) | 15.87(12.21,21.22) | |||||||||
7~12 | 30 | 21.37(19.27,31.08) | 13.43(12.38,26.46) | |||||||||
>12 | 17 | 22.77(20.27,25.09) | 13.66(11.92,15.99) | |||||||||
COS方案 | -0.101 | 0.920 | -0.666 | 0.505 | ||||||||
长方案 | 34 | 21.97(20.87,25.75) | 14.24(12.21,19.59) | |||||||||
拮抗剂方案 | 30 | 22.87(19.17,30.57) | 14.94(12.50,19.83) | |||||||||
Gn剂量(IU) | -1.054 | 0.292 | -0.900 | 0.368 | ||||||||
<2 512 | 32 | 22.77(20.22,28.43) | 14.36(12.09,18.14) | |||||||||
≥2 512 | 32 | 21.37(19.42,26.40) | 14.82(12.44,21.92) | |||||||||
Gn天数(d) | -1.138 | 0.255 | -0.838 | 0.402 | ||||||||
<12 | 59 | 21.77(19.57,27.62) | 14.59(12.26,19.01) | |||||||||
≥12 | 5 | 24.99(22.76,27.92) | 15.52(12.96,28.78) |
指标 | 检出率(%) | MDL | P25 | P50 | P75 |
---|---|---|---|---|---|
MEP(ng/mL) | 76.5 | 0.14 | 0.15 | 0.49 | 2.36 |
MBP(ng/mL) | 100.0 | 0.30 | 2.20 | 4.26 | 7.53 |
MiBP(ng/mL) | 93.7 | 0.16 | 1.42 | 7.83 | 13.12 |
MCMHP(ng/mL) | 100.0 | 0.01 | 0.21 | 0.62 | 0.82 |
MECPP(ng/mL) | 100.0 | 0.01 | 0.13 | 0.21 | 0.54 |
MEHHP(ng/mL) | 100.0 | 0.01 | 0.13 | 0.25 | 0.62 |
MEOHP(ng/mL) | 100.0 | 0.01 | 0.09 | 0.13 | 0.46 |
MEHP(ng/mL) | 79.7 | 0.11 | 2.12 | 4.39 | 11.17 |
TNF-α(pg/mL) | 100.0 | 4.32 | 19.67 | 22.27 | 27.57 |
IL-6(pg/mL) | 100.0 | 1.60 | 12.26 | 14.59 | 19.36 |
表2 FF中mPAEs及炎性因子的浓度及分布情况
指标 | 检出率(%) | MDL | P25 | P50 | P75 |
---|---|---|---|---|---|
MEP(ng/mL) | 76.5 | 0.14 | 0.15 | 0.49 | 2.36 |
MBP(ng/mL) | 100.0 | 0.30 | 2.20 | 4.26 | 7.53 |
MiBP(ng/mL) | 93.7 | 0.16 | 1.42 | 7.83 | 13.12 |
MCMHP(ng/mL) | 100.0 | 0.01 | 0.21 | 0.62 | 0.82 |
MECPP(ng/mL) | 100.0 | 0.01 | 0.13 | 0.21 | 0.54 |
MEHHP(ng/mL) | 100.0 | 0.01 | 0.13 | 0.25 | 0.62 |
MEOHP(ng/mL) | 100.0 | 0.01 | 0.09 | 0.13 | 0.46 |
MEHP(ng/mL) | 79.7 | 0.11 | 2.12 | 4.39 | 11.17 |
TNF-α(pg/mL) | 100.0 | 4.32 | 19.67 | 22.27 | 27.57 |
IL-6(pg/mL) | 100.0 | 1.60 | 12.26 | 14.59 | 19.36 |
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -1.802(-5.564~1.961) | -0.148 | 0.341 | -1.760(-4.498~0.978) | -0.191 | 0.203 |
MBP | 0.168(0.059~0.278) | 0.446 | 0.003 | 0.121(0.042~0.201) | 0.425 | 0.003 |
MiBP | 0.141(-0.348~0.630) | 0.081 | 0.565 | 0.106(-0.250~0.462) | 0.081 | 0.553 |
MCMHP | -3.372(-8.583~1.840) | -0.204 | 0.200 | -0.077(-3.869~3.715) | -0.006 | 0.968 |
MECPP | -7.410(-19.278~4.458) | -0.201 | 0.216 | 0.217(-8.418~8.853) | 0.008 | 0.960 |
MEHHP | -3.062(-18.892~12.768) | -0.060 | 0.699 | -4.205(-15.723~7.314) | -0.110 | 0.467 |
MEOHP | 22.851(3.966~41.735) | 0.411 | 0.019 | -0.998(-14.739~12.743) | -0.024 | 0.885 |
MEHP | -0.087(-0.791~0.617) | -0.037 | 0.804 | 0.219(-0.293~0.731) | 0.121 | 0.395 |
表3 FF中mPAEs与炎性因子水平的关系
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -1.802(-5.564~1.961) | -0.148 | 0.341 | -1.760(-4.498~0.978) | -0.191 | 0.203 |
MBP | 0.168(0.059~0.278) | 0.446 | 0.003 | 0.121(0.042~0.201) | 0.425 | 0.003 |
MiBP | 0.141(-0.348~0.630) | 0.081 | 0.565 | 0.106(-0.250~0.462) | 0.081 | 0.553 |
MCMHP | -3.372(-8.583~1.840) | -0.204 | 0.200 | -0.077(-3.869~3.715) | -0.006 | 0.968 |
MECPP | -7.410(-19.278~4.458) | -0.201 | 0.216 | 0.217(-8.418~8.853) | 0.008 | 0.960 |
MEHHP | -3.062(-18.892~12.768) | -0.060 | 0.699 | -4.205(-15.723~7.314) | -0.110 | 0.467 |
MEOHP | 22.851(3.966~41.735) | 0.411 | 0.019 | -0.998(-14.739~12.743) | -0.024 | 0.885 |
MEHP | -0.087(-0.791~0.617) | -0.037 | 0.804 | 0.219(-0.293~0.731) | 0.121 | 0.395 |
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -0.226(-2.990~2.538) | -0.026 | 0.869 | -2.167(-6.175~1.840) | -0.198 | 0.279 |
MBP | 0.143(0.076~0.210) | 0.667 | 0.000 | 0.110(0.013~0.207) | 0.407 | 0.028 |
MiBP | 0.229(-0.109~0.567) | 0.199 | 0.178 | 0.177(-0.313~0.667) | 0.122 | 0.467 |
MCMHP | -2.053(-8.689~4.582) | -0.124 | 0.533 | 0.950(-8.671~10.571) | 0.046 | 0.842 |
MECPP | -1.400(-9.128~6.327) | -0.064 | 0.715 | -0.794(-11.998~10.410) | -0.029 | 0.886 |
MEHHP | -4.357(-15.130~6.416) | -0.130 | 0.416 | -9.512(-25.131~6.108) | -0.226 | 0.224 |
MEOHP | 8.444(-5.425~22.312) | 0.242 | 0.224 | 2.861(-17.247~22.969) | 0.065 | 0.774 |
MEHP | 0.058(-0.406~0.523) | 0.036 | 0.800 | 0.128(-0.546~0.801) | 0.063 | 0.702 |
表4 年龄≥30岁患者FF中mPAEs与炎性因子水平的关系
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -0.226(-2.990~2.538) | -0.026 | 0.869 | -2.167(-6.175~1.840) | -0.198 | 0.279 |
MBP | 0.143(0.076~0.210) | 0.667 | 0.000 | 0.110(0.013~0.207) | 0.407 | 0.028 |
MiBP | 0.229(-0.109~0.567) | 0.199 | 0.178 | 0.177(-0.313~0.667) | 0.122 | 0.467 |
MCMHP | -2.053(-8.689~4.582) | -0.124 | 0.533 | 0.950(-8.671~10.571) | 0.046 | 0.842 |
MECPP | -1.400(-9.128~6.327) | -0.064 | 0.715 | -0.794(-11.998~10.410) | -0.029 | 0.886 |
MEHHP | -4.357(-15.130~6.416) | -0.130 | 0.416 | -9.512(-25.131~6.108) | -0.226 | 0.224 |
MEOHP | 8.444(-5.425~22.312) | 0.242 | 0.224 | 2.861(-17.247~22.969) | 0.065 | 0.774 |
MEHP | 0.058(-0.406~0.523) | 0.036 | 0.800 | 0.128(-0.546~0.801) | 0.063 | 0.702 |
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -2.155(-21.310~17.001) | -0.133 | 0.805 | -0.168(-6.699~6.363) | -0.035 | 0.955 |
MBP | -1.030(-4.008~1.947) | -0.345 | 0.454 | 0.360(-0.655~1.376) | 0.412 | 0.443 |
MiBP | 0.445(-1.546~2.436) | 0.170 | 0.625 | -0.065(-0.744~0.614) | -0.084 | 0.834 |
MCMHP | -5.528(-18.762~7.707) | -0.345 | 0.369 | 0.494(-4.018~5.007) | 0.105 | 0.810 |
MECPP | -67.015(-163.670~29.641) | -0.721 | 0.151 | 8.382(-24.571~41.336) | 0.308 | 0.579 |
MEHHP | 16.335(-57.953~90.624) | 0.209 | 0.631 | 4.072(-21.255~29.400) | 0.178 | 0.724 |
MEOHP | 79.435(-10.351~169.222) | 0.789 | 0.076 | -10.809(-41.420~19.803) | -0.367 | 0.445 |
MEHP | 0.592(-3.611~4.796) | 0.169 | 0.757 | -0.302(-1.735~1.131) | -0.295 | 0.645 |
表5 年龄<30岁患者FF中mPAEs与炎性因子水平的关系
mPAEs | TNF-α | IL-6 | ||||
---|---|---|---|---|---|---|
B(95%CI) | β | P | B(95%CI) | β | P | |
MEP | -2.155(-21.310~17.001) | -0.133 | 0.805 | -0.168(-6.699~6.363) | -0.035 | 0.955 |
MBP | -1.030(-4.008~1.947) | -0.345 | 0.454 | 0.360(-0.655~1.376) | 0.412 | 0.443 |
MiBP | 0.445(-1.546~2.436) | 0.170 | 0.625 | -0.065(-0.744~0.614) | -0.084 | 0.834 |
MCMHP | -5.528(-18.762~7.707) | -0.345 | 0.369 | 0.494(-4.018~5.007) | 0.105 | 0.810 |
MECPP | -67.015(-163.670~29.641) | -0.721 | 0.151 | 8.382(-24.571~41.336) | 0.308 | 0.579 |
MEHHP | 16.335(-57.953~90.624) | 0.209 | 0.631 | 4.072(-21.255~29.400) | 0.178 | 0.724 |
MEOHP | 79.435(-10.351~169.222) | 0.789 | 0.076 | -10.809(-41.420~19.803) | -0.367 | 0.445 |
MEHP | 0.592(-3.611~4.796) | 0.169 | 0.757 | -0.302(-1.735~1.131) | -0.295 | 0.645 |
[1] | Tian X, Qin B, Yang L, et al. Association of phthalate exposure with reproductive outcomes among infertile couples undergoing in vitro fertilization: A systematic review[J]. Environ Res, 2024, 252(Pt 2):118825. doi: 10.1016/j.envres.2024.118825. |
[2] | Li J, Liu B, Yu Y, et al. A systematic review of global distribution, sources and exposure risk of phthalate esters (PAEs) in indoor dust[J]. J Hazard Mater, 2024, 471:134423. doi: 10.1016/j.jhazmat.2024.134423. |
[3] |
Zhou M, Ford B, Lee D, et al. Metabolomic Markers of Phthalate Exposure in Plasma and Urine of Pregnant Women[J]. Front Public Health, 2018, 6:298. doi: 10.3389/fpubh.2018.00298.
pmid: 30406068 |
[4] | Artini PG, Scarfò G, Marzi I, et al. Oxidative Stress-Related Signaling Pathways Predict Oocytes′ Fertilization In Vitro and Embryo Quality[J]. Int J Mol Sci, 2022, 23(21):13442. doi: 10.3390/ijms232113442. |
[5] | Rostami S, Alyasin A, Saedi M, et al. Astaxanthin ameliorates inflammation, oxidative stress, and reproductive outcomes in endometriosis patients undergoing assisted reproduction: A randomized, triple-blind placebo-controlled clinical trial[J]. Front Endocrinol(Lausanne), 2023, 14:1144323. doi: 10.3389/fendo.2023.1144323. |
[6] | Li Y, Yao Y, Xiao N, et al. The association of serum phthalate metabolites with biomarkers of ovarian reserve in women of childbearing age[J]. Ecotoxicol Environ Saf, 2022, 242:113909. doi: 10.1016/j.ecoenv.2022.113909. |
[7] | Li Y, Xiao N, Liu M, et al. Dysregulation of steroid metabolome in follicular fluid links phthalate exposure to diminished ovarian reserve of childbearing-age women[J]. Environ Pollut, 2023, 330:121730. doi: 10.1016/j.envpol.2023.121730. |
[8] | Wang Y, Du YY, Yao W, et al. Associations between phthalate metabolites and cytokines in the follicular fluid of women undergoing in vitro fertilization[J]. Ecotoxicol Environ Saf, 2023, 267:115616. doi: 10.1016/j.ecoenv.2023.115616. |
[9] |
Chen Q, Yang H, Zhou N, et al. Phthalate exposure, even below US EPA reference doses, was associated with semen quality and reproductive hormones: Prospective MARHCS study in general population[J]. Environ Int, 2017, 104:58-68. doi: 10.1016/j.envint.2017.04.005.
pmid: 28441547 |
[10] |
Ding M, Kang Q, Zhang S, et al. Contribution of phthalates and phthalate monoesters from drinking water to daily intakes for the general population[J]. Chemosphere, 2019, 229:125-131. doi: 10.1016/j.chemosphere.2019.05.023.
pmid: 31078027 |
[11] |
Peters A, Nawrot TS, Baccarelli AA. Hallmarks of environmental insults[J]. Cell, 2021, 184(6):1455-1468. doi: 10.1016/j.cell.2021.01.043.
pmid: 33657411 |
[12] |
Qiao J, Feng HL. Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence[J]. Hum Reprod Update, 2011, 17(1):17-33. doi: 10.1093/humupd/dmq032.
pmid: 20639519 |
[13] | Baskind NE, Orsi NM, Sharma V. Follicular-phase ovarian follicular fluid and plasma cytokine profiling of natural cycle in vitro fertilization patients[J]. Fertil Steril, 2014, 102(2):410-418. doi: 10.1016/j.fertnstert.2014.04.032. |
[14] |
Bukulmez O, Arici A. Leukocytes in ovarian function[J]. Hum Reprod Update, 2000, 6(1):1-15. doi: 10.1093/humupd/6.1.1.
pmid: 10711825 |
[15] | Chen SU, Chou CH, Lee H, et al. Lysophosphatidic acid up-regulates expression of interleukin-8 and -6 in granulosa-lutein cells through its receptors and nuclear factor-kappaB dependent pathways: implications for angiogenesis of corpus luteum and ovarian hyperstimulation syndrome[J]. J Clin Endocrinol Metab, 2008, 93(3):935-943. doi: 10.1210/jc.2007-1512. |
[16] | Inoue N, Matsuda F, Goto Y, et al. Role of cell-death ligand-receptor system of granulosa cells in selective follicular atresia in porcine ovary[J]. J Reprod Dev, 2011, 57(2):169-175. doi: 10.1262/jrd.10-198e. |
[17] | Liu Z, Lu Y, Zhong K, et al. The associations between endocrine disrupting chemicals and markers of inflammation and immune responses: A systematic review and meta-analysis[J]. Ecotoxicol Environ Saf, 2022, 234:113382. doi: 10.1016/j.ecoenv.2022.113382. |
[18] | Li L, Xia Y, Chen J, et al. DBP exposure induces thyroid inflammatory impairment through activating AKT/NF-κB/NLRP3 signaling[J]. Ecotoxicol Environ Saf, 2023, 264:115385. doi: 10.1016/j.ecoenv.2023.115385. |
[19] | Czubacka E, Czerczak S, Kupczewska-Dobecka MM. The overview of current evidence on the reproductive toxicity of dibutyl phthalate[J]. Int J Occup Med Environ Health, 2021, 34(1):15-37. doi: 10.13075/ijomeh.1896.01658. |
[20] |
Curry TE Jr, Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle[J]. Endocr Rev, 2003, 24(4):428-465. doi: 10.1210/er.2002-0005.
pmid: 12920150 |
[21] | Altun T, Jindal S, Greenseid K, et al. Low follicular fluid IL-6 levels in IVF patients are associated with increased likelihood of clinical pregnancy[J]. J Assist Reprod Genet, 2011, 28(3):245-251. doi: 10.1007/s10815-010-9502-8. |
[22] |
Bai PY, Wittert G, Taylor AW, et al. The association between total phthalate concentration and non-communicable diseases and chronic inflammation in South Australian urban dwelling men[J]. Environ Res, 2017, 158:366-372. doi: 10.1016/j.envres.2017.06.021.
pmid: 28686951 |
[23] | Zhang L, Ruan Z, Jing J, et al. High-Temperature Soup Foods in Plastic Packaging Are Associated with Phthalate Body Burden and Expression of Inflammatory mRNAs: A Dietary Intervention Study[J]. Environ Sci Technol, 2022, 56(12):8416-8427. doi: 10.1021/acs.est.1c08522. |
[24] |
Duan Y, Wang L, Han L, et al. Exposure to phthalates in patients with diabetes and its association with oxidative stress, adiponectin, and inflammatory cytokines[J]. Environ Int, 2017, 109:53-63. doi: 10.1016/j.envint.2017.09.002.
pmid: 28938100 |
[25] | Xiong Z, Zeng Y, Zhou J, et al. Exposure to dibutyl phthalate impairs lipid metabolism and causes inflammation via disturbing microbiota-related gut-liver axis[J]. Acta Biochim Biophys Sin(Shanghai), 2020, 52(12):1382-1393. doi: 10.1093/abbs/gmaa128. |
[26] |
Nishioka J, Iwahara C, Kawasaki M, et al. Di-(2-ethylhexyl) phthalate induces production of inflammatory molecules in human macrophages[J]. Inflamm Res, 2012, 61(1):69-78. doi: 10.1007/s00011-011-0390-x.
pmid: 22005928 |
[27] | Lee KS, Joo BS, Na YJ, et al. Relationships between concentrations of tumor necrosis factor-alpha and nitric oxide in follicular fluid and oocyte quality[J]. J Assist Reprod Genet, 2000, 17(4):222-228. doi: 10.1023/a:1009495913119. |
[1] | 吴宇轩, 孟子凡, 董丽, 季慧. 宫腔镜子宫内膜息肉手术后冻融胚胎移植时机对妊娠结局的影响[J]. 国际生殖健康/计划生育杂志, 2024, 43(4): 274-278. |
[2] | 张爱玉, 栾翠玉, 王冬梅, 蒋帅. IVF-ET不孕症患者就医延迟现状及影响因素分析[J]. 国际生殖健康/计划生育杂志, 2024, 43(3): 190-194. |
[3] | 谷旭照, 沈豪飞, 高敏, 刘阿慧, 王娜, 杨雯景, 张学红. 双子宫合并卵巢妊娠一例[J]. 国际生殖健康/计划生育杂志, 2024, 43(2): 118-120. |
[4] | 郝佳丽, 何玉洁. 不孕不育人群生育生活质量评价及其影响因素分析[J]. 国际生殖健康/计划生育杂志, 2024, 43(2): 159-165. |
[5] | 梁俊霞, 杨堉杰, 张丽, 葛丽娜, 王娜娜, 田瑛, 刘鹏, 闫蒙. 高龄女性IVF/ICSI无可利用胚胎危险因素探讨[J]. 国际生殖健康/计划生育杂志, 2024, 43(1): 1-6. |
[6] | 闫惠惠, 张云山. 嵌合体胚胎移植的临床研究现状[J]. 国际生殖健康/计划生育杂志, 2023, 42(6): 503-506. |
[7] | 牛国燕, 熊正方. 经阴道超声引导下穿刺取卵术镇痛方式的研究进展[J]. 国际生殖健康/计划生育杂志, 2023, 42(6): 507-512. |
[8] | 陈寅, 王菁, 冒韵东. 子宫内膜异位症合并不孕患者的控制性卵巢刺激方案研究进展[J]. 国际生殖健康/计划生育杂志, 2023, 42(5): 398-402. |
[9] | 倪丹玉, 杨烨, 谢奇君, 姜薇, 凌秀凤. 卵细胞质内单精子注射后多原核发生率对胚胎发育和妊娠结局的影响[J]. 国际生殖健康/计划生育杂志, 2023, 42(4): 272-276. |
[10] | 姚汝强, 王昕妍, 刁俊荣, 张星星, 张云山, 罗海宁. 剖宫产史对IVF/ICSI-ET治疗累积活产率的影响[J]. 国际生殖健康/计划生育杂志, 2023, 42(3): 177-183. |
[11] | 陈楸妍, 鲁南, 刘嘉茵. 生长激素预处理在前次IVF/ICSI失败非DOR患者中的临床应用[J]. 国际生殖健康/计划生育杂志, 2023, 42(3): 184-188. |
[12] | 王春艳, 王婕妤, 程静娴, 王吟霜, 罗桂英. 辅助生殖技术与子代安全[J]. 国际生殖健康/计划生育杂志, 2023, 42(3): 226-230. |
[13] | 张笑兰, 武恂, 曹善仁, 张军强, 凌秀凤, 李秀玲. 冻融胚胎行植入前遗传学检测的安全性与临床结局分析[J]. 国际生殖健康/计划生育杂志, 2023, 42(2): 102-106. |
[14] | 霍文杰, 王晓聪, 彭飞, 全松. 深度学习在体外受精胚胎优选中的应用[J]. 国际生殖健康/计划生育杂志, 2023, 42(2): 135-139. |
[15] | 赵海君, 张皙卉, 陈静, 卢静, 张洪峰, 常文亮. 三种促排卵方案在高龄合并卵巢储备功能减退不孕症中的应用比较[J]. 国际生殖健康/计划生育杂志, 2023, 42(1): 13-17. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||